Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$14.56
$0.53(4.50%)
At close: 4:00 PM EDT
$14.56
$0.53(4.50%)
Day’s Range― - ―
52-Week Range$6.62 - $15.35
Previous Close$12.35
Volume585.80K
Average Volume (3M)987.26K
Market Cap
$957.55M
Enterprise Value$1.24B
Total Cash (Recent Filing)$143.17M
Total Debt (Recent Filing)$112.32M
Price to Earnings (P/E)13.0
Beta1.67
Next Earnings
Nov 18, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding96,043,000
10 Day Avg. Volume960,315
30 Day Avg. Volume987,256
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda4.71
Forecast
1Y Price Target
$22.40Price Target Upside53.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.31
Revenue Forecast (FY)$337.59M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability InflectionThe sharp TTM increase in revenue and return to profitability indicate meaningful commercial progress, while exceptionally high reported margins could support reinvestment and earnings growth. If sustained, this inflection would strengthen the company’s operating position over the next several quarters.
Manageable TTM LeverageCurrent leverage appears manageable relative to equity, providing more financial flexibility than a highly indebted capital structure would allow. This balance-sheet position may help the company fund operations and strategic initiatives while reducing near-term pressure from debt obligations.
Experienced Strategic OversightAdding a veteran healthcare investor to the board can strengthen strategic oversight as MeiraGTx transitions toward a commercial genetic medicines company. His stated experience in biopharmaceutical finance and governance may support disciplined portfolio decisions and execution across late-stage programs.
Bears Say
Unproven Earnings DurabilityThe recent profit rebound follows several years of heavy losses, making the new earnings profile difficult to regard as established. This history raises the risk that margins and net income could remain volatile, limiting confidence in durable earnings power over the next several quarters.
Weak Cash ConversionPositive TTM cash flow is encouraging, but conversion materially trails reported net income and follows a prolonged period of negative cash generation. Until operating profits translate more consistently into cash, funding flexibility and the quality of the recovery remain exposed to renewed volatility.
Prior Balance-Sheet StressAlthough TTM leverage has improved, the recent history of slightly negative equity shows that balance-sheet quality has not been stable across reporting periods. Prior stress can constrain financial flexibility and makes the company more dependent on sustained profitability to preserve its improved capital position.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings Plc’s price range in the past 12 months?
Meiragtx Holdings Plc lowest stock price was $6.62 and its highest was $15.35 in the past 12 months.
What is Meiragtx Holdings Plc’s market cap?
Meiragtx Holdings Plc’s market cap is $957.55M.
When is Meiragtx Holdings Plc’s upcoming earnings report date?
Meiragtx Holdings Plc’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.
How were Meiragtx Holdings Plc’s earnings last quarter?
Meiragtx Holdings Plc released its earnings results on Aug 13, 2026. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of -$0.458 by $2.168.
Is Meiragtx Holdings Plc overvalued?
According to Wall Street analysts Meiragtx Holdings Plc’s price is currently Undervalued.
Does Meiragtx Holdings Plc pay dividends?
Meiragtx Holdings Plc does not currently pay dividends.
What is Meiragtx Holdings Plc’s EPS estimate?
Meiragtx Holdings Plc’s EPS estimate is -0.5.
How many shares outstanding does Meiragtx Holdings Plc have?
Meiragtx Holdings Plc has 96,043,000 shares outstanding.
What happened to Meiragtx Holdings Plc’s price movement after its last earnings report?
Meiragtx Holdings Plc reported an EPS of $1.71 in its last earnings report, beating expectations of -$0.458. Following the earnings report the stock price went down -2.238%.
Which hedge fund is a major shareholder of Meiragtx Holdings Plc?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.40 (53.85% Upside)
$22.40 (53.85% Upside)
Blogger Sentiment
Neutral
MGTX Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.47%
12-Months-Change
Fundamentals
Return on Equity
284.38%
Trailing 12-Months
Asset Growth
99.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Meiragtx Holdings Plc
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$22.40
▲(53.85% Upside)
Technical Analysis
uniQure
―
RegenXBio
―
Solid Biosciences
―
Taysha Gene Therapies
―
4D Molecular Therapeutics
―
Ownership Overview
14.85% Insiders
1.79% Mutual Funds
0.76% Other Institutional Investors
76.19% Public Companies and
Individual Investors